[CAS NO. 315704-66-6] PTC-209
PRODUCTS SPECIFICATIONS [315704-66-6]
DESCRIPTION [315704-66-6]
Overview
| MDL | MFCD02110649 |
|---|---|
| Molecular Weight | 495.19 |
| Molecular Formula | C17H13Br2N5OS |
| SMILES | CC1=C(C2=CSC(NC3=C(Br)C=C(OC)C=C3Br)=N2)N4C=CC=NC4=N1 |
9 Publications Citing Use of MCE
- [1]Cell Stem Cell. 2017 May 4;20(5):621-634.e6.
- [2]Nat Commun. 2018 Feb 5;9(1):500.
- [3]Oncogene. 2020 Jan;39(1):17-29.
- [4]Cancers (Basel). 2022, 14(23), 5947.
- [5]Pharmacol Res. 2020 Dec 8;105365.
- [6]Front Oncol. 2021 Mar 22;11:620295.
- [7]Apoptosis. 2015 Jan;20(1):75-82.
- [8]Stem Cells Int. 2020 Aug 20;2020:8877577.
- [9]University of Glasgow. College of Medical, Veterinary and Life Science.
Summary
IC50 & Target
IC50: 0.5 μM (BMI-1, in HT1080 tumor cells) [1]
In Vitro
PTC-209 (0.01-10 µM; 24-72 hours) induces a concentration- and time-dependent decrease in the cellular viability of all cell lines tested
[2]
.
PTC-209 (1-2.5 μM) inhibits STAT3 phosphorylation in A549 lung cancer cells and MDA-MB-231 breast cancer cells
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [2]
| Cell Line: | Lung (LNM35, A549 cells), breast (MDA-MB-231 and T47D cells), and colon (HT-29, HCT-116, and HCT8/S11 cells) |
| Concentration: | 0.01-10 µM |
| Incubation Time: | 24, 48, and 72 hour |
| Result: | Induced a concentration- and time-dependent decrease in the cellular viability of all cell lines tested. |
In Vivo
PTC-209 (60 mg/kg body weight; subcutaneously; once a day for 11 days) significantly reduces tumor volume [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Nude mice (male, aged 8-10 weeks, HCT1116 cell-derived tumor) [1] |
| Dosage: | 60 mg/kg body weight |
| Administration: | Subcutaneously; once a day for 11 days |
| Result: | Significantly reduced tumor volume |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 32 mg/mL ( 64.62 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0194 mL | 10.0971 mL | 20.1943 mL |
| 5 mM | 0.4039 mL | 2.0194 mL | 4.0389 mL |
| 10 mM | 0.2019 mL | 1.0097 mL | 2.0194 mL |
-
1.
References
- [1] Kreso A, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014 Jan;20(1):29-36.
- [2] Sulaiman S, et al. PTC-209 Anti-Cancer Effects Involved the Inhibition of STAT3 Phosphorylation. Front Pharmacol. 2019;10:1199. Published 2019 Oct 21.
- [3] Chen D, et al. Targeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma. Cell Stem Cell. 2017 May 4;20(5):621-634.e6.